Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nils Ternes"'
Autor:
Nan Lin, Amy Damask, Anita Boyapati, Jennifer D. Hamilton, Sara Hamon, Nils Ternes, Michael C. Nivens, John Penn, Alexander Lopez, Jeffrey G. Reid, John Overton, Alan R. Shuldiner, Goncalo Abecasis, Aris Baras, Charles Paulding
Publikováno v:
The Pharmacogenomics Journal. 22:160-165
Sarilumab is a human monoclonal antibody against interleukin (IL)-6Rα that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one or more di
Autor:
Hiroji Iwata, Aditya Bardia, Simon Lord, Hannah M. Linden, Mario Campone, Kenji Tamura, Kan Yonemori, Toru Mukohara, Cécile Combeau, Nils Ternes, Dimitri Carene, Jeff Ming, Joon Sang Lee, Marina Celanovic, Anne-Laure Bauchet, Monsif Bouaboula, Tomoyuki Tanaka, Yumiko Kawabata, Sarat Chandarlapaty
Publikováno v:
Cancer Research. 82:CT517-CT517
Background: Amcenestrant is an optimized oral SERD that has shown safety and clinical benefit in patients (pts) with wild-type (WT) and mutated ESR1 aBC. Here we provide a pooled analysis of biomarkers from two studies in heavily-pretreated, postmeno
Autor:
Emma Wang, Alice Gosselin, Alexei Protopopov, Colette Dib, Joon Sang Lee, Maysoun Shomali, Vasiliki Pelekanou, Nils Ternes, Christopher Soria, Patrick Cohen, Marina Celanovic, Monsif Bouaboula, Wilson Dos-Santos-Bele, Jack Pollard, Eric Boitier
Publikováno v:
Cancer Research. 81:406-406
Hormone or endocrine therapy is the primary treatment for estrogen receptor-positive (ER+) breast cancer. Selective Estrogen Receptor Modulators (SERMs) have been used for women with ER+ invasive cancer in the adjuvant setting. However, they do not f
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-20 (2023)
Abstract In clinical trials, identification of prognostic and predictive biomarkers has became essential to precision medicine. Prognostic biomarkers can be useful for the prevention of the occurrence of the disease, and predictive biomarkers can be
Externí odkaz:
https://doaj.org/article/a9630ca2a427495abeb9e38edf0483bc
Autor:
Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with
Externí odkaz:
https://doaj.org/article/896c8c572eae40909c4db5b12e799b6b
Publikováno v:
BMC Medical Research Methodology, Vol 17, Iss 1, Pp 1-12 (2017)
Abstract Background Thanks to the advances in genomics and targeted treatments, more and more prediction models based on biomarkers are being developed to predict potential benefit from treatments in a randomized clinical trial. Despite the methodolo
Externí odkaz:
https://doaj.org/article/0d8689a8b73b4beeb5b5fa5bcc84b142